🇺🇸 FDA
Pipeline program

JNJ-78278343, Docetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, JNJ-78278343, Prednison acis 5 mg, Tabletten, DOCETAXEL , PREDNISONE

78278343PCR3003

Phase 3 small_molecule active

Quick answer

JNJ-78278343, Docetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, JNJ-78278343, Prednison acis 5 mg, Tabletten, DOCETAXEL , PREDNISONE for Metastatic Castration-resistant Prostate Cancer (mCRPC) is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Janssen-Cilag International N.V.
Indication
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials